Live Price Coverage: A Reversal for Genomic Health, Inc. Is Not Near. The Stock Declines Again

Live Price Coverage: A Reversal for Genomic Health, Inc. Is Not Near. The Stock Declines Again

The stock of Genomic Health, Inc. (NASDAQ:GHDX) is a huge mover today! About 118,259 shares traded hands. Genomic Health, Inc. (NASDAQ:GHDX) has risen 20.86% since March 9, 2016 and is uptrending. It has outperformed by 13.44% the S&P500.
The move comes after 9 months negative chart setup for the $961.65 million company. It was reported on Oct, 12 by We have $26.82 PT which if reached, will make NASDAQ:GHDX worth $76.93M less.

Analysts await Genomic Health, Inc. (NASDAQ:GHDX) to report earnings on November, 1. They expect $-0.08 earnings per share, up 77.78% or $0.28 from last year’s $-0.36 per share. After $-0.18 actual earnings per share reported by Genomic Health, Inc. for the previous quarter, Wall Street now forecasts -55.56% EPS growth.

Genomic Health, Inc. (NASDAQ:GHDX) Ratings Coverage

Out of 6 analysts covering Genomic Health (NASDAQ:GHDX), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. Genomic Health has been the topic of 17 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The company was downgraded on Monday, January 11 by Piper Jaffray. Barclays Capital initiated Genomic Health, Inc. (NASDAQ:GHDX) rating on Wednesday, September 2. Barclays Capital has “Underweight” rating and $25.0 price target. The stock of Genomic Health, Inc. (NASDAQ:GHDX) has “Market Perform” rating given on Friday, August 28 by Raymond James. The stock of Genomic Health, Inc. (NASDAQ:GHDX) earned “Buy” rating by UBS on Monday, November 23. Canaccord Genuity maintained Genomic Health, Inc. (NASDAQ:GHDX) rating on Wednesday, August 5. Canaccord Genuity has “Hold” rating and $26 price target. The rating was upgraded by Raymond James to “Outperform” on Wednesday, November 4. Zacks downgraded the shares of GHDX in a report on Thursday, August 6 to “Hold” rating. The firm earned “Sell” rating on Monday, August 24 by Zacks. On Wednesday, January 6 the stock rating was upgraded by Canaccord Genuity to “Buy”. On Wednesday, August 17 the stock rating was maintained by Jefferies with “Hold”.

According to Zacks Investment Research, “Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.”

Insitutional Activity: The institutional sentiment decreased to 1.56 in Q2 2016. Its down 0.13, from 1.69 in 2016Q1. The ratio fall, as 11 funds sold all Genomic Health, Inc. shares owned while 30 reduced positions. 19 funds bought stakes while 45 increased positions. They now own 29.46 million shares or 0.97% less from 29.75 million shares in 2016Q1.
Comml Bank Of Montreal Can holds 0% or 7,220 shares in its portfolio. Teacher Retirement System Of Texas last reported 2,511 shares in the company. Pacad Investment Ltd reported 2,500 shares or 0.01% of all its holdings. The Sweden-based Nordea Investment Ab has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). Goldman Sachs Group Inc Inc holds 112,057 shares or 0% of its portfolio. Berson And Corrado Invest Ltd Com last reported 40,695 shares in the company. Acuta Capital Prns Ltd Llc reported 48,800 shares or 0.61% of all its holdings. Fmr Limited Company has 0% invested in the company for 525,148 shares. Tpg (Sbs) last reported 260,273 shares in the company. Hbk Invs L P holds 0.01% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX) for 30,666 shares. Blackrock Japan reported 806 shares or 0% of all its holdings. Millennium Limited reported 836,285 shares or 0.05% of all its holdings. Glenmede Trust Na has invested 0% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX). Secor Cap L P holds 0.19% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX) for 57,893 shares. The Colorado-based Pub Employees Retirement Association Of Colorado has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX).

Insider Transactions: Since May 4, 2016, the stock had 1 insider buy, and 14 sales for $922,251 net activity. Cole G Bradley had sold 5,000 shares worth $133,223. The insider Febbo Phillip G. sold $172,034. Shak Steven also sold $136,215 worth of Genomic Health, Inc. (NASDAQ:GHDX) on Tuesday, August 23. $56,000 worth of shares were sold by Vaughn James J on Monday, May 9. The insider BAKER FELIX bought 100,000 shares worth $2.70 million.

More notable recent Genomic Health, Inc. (NASDAQ:GHDX) news were published by: which released: “Genomic Health, Inc. Earnings: Waiting for (More) Reimbursement” on May 11, 2016, also with their article: “Genomic Health, Inc. Pushes Toward Profitability” published on August 04, 2016, published: “Genomic Health, Inc. Eyes Profitability” on February 11, 2016. More interesting news about Genomic Health, Inc. (NASDAQ:GHDX) were released by: and their article: “3 Things to Watch as Genomic Health, Inc. Reports Earnings” published on August 01, 2016 as well as‘s news article titled: “Why Genomic Health, Inc. Earned a Higher Share Price” with publication date: May 05, 2016.

GHDX Company Profile

Genomic Health, Inc., incorporated on August 22, 2000, is a healthcare company, which provides genomic diagnostic tests for the treatment of early stage cancer. The Firm offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment